Tag: prospectus

DALLAS, July 15, 2025 (GLOBE NEWSWIRE) -- Veritex Holdings, Inc. (Nasdaq: VBTX), the parent holding company for Veritex Community Bank, today announced a date change for release of its second quarter 2025 earnings results. Veritex will now release its second quarter 2025 earnings results before the opening of the market on Friday, July 18, 2025. The earnings release will be available on Veritex’s website, https://ir.veritexbank.com/.

Hong Kong, July 15, 2025 (GLOBE NEWSWIRE) -- K-Tech Solutions Company Limited (“KMRK” or the “Company”) is an established toy products design house specialized in the development of infant and pre-school educational toys and learning kits. The Company is headquartered in Hong Kong to provide full-fledged product development solutions to toy brands throughout the entire development stage of toy products from design, prototype testing, production management, quality control to after-sales services. K-Tech Solutions Company Limited today announced the pricing of its firm commitment initial public offering of an aggregate 1,600,000 Class A Shares (the “Offering”) priced at US$4.00 per share (the “Offering Price”). In addition, the Company has granted the underwriter a 30-day option ("Overallotment") to purchase up to an additional 240,000 Class A Shares at the initial public offering price, less underwriting discounts and commissions.

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent fees and offering expenses. Each Warrant is immediately exercisable, and entitles the holder to purchase one common share at an exercise price of $1.50 per share and will expire five years from the date of issuance. The common shares (or Pre-Funded Warrants) and Warrants can only be purchased together in the offering but will be issued separately.

CARLSBAD, California, July 15, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced it will be participating in the 7th Annual ASPN Conference sponsored by The American Society of Pain Neuroscience (ASPN) to be held July 17-20 at the Fontainebleu Miami Hotel in Miami Beach, Florida. Aurora will be located at Booth 129/130.

To kick off the first full day of the conference (July 18th), there will be a series of discussions starting with a General Session on ‘Embracing Disruption, Driving Innovation. Minimally Invasive Spine.’ Within this General Session, there will be two discussions with relevancy to Aurora Spine products: Surgical Approaches to Facet Disease and Posterior Approaches to Lumbar Spine and SI Joint.

On Saturday, July 19^th, Aurora’s ZIP product series will be highlighted in an ASPN Top Abstract discussion, of which only 12 are selected out of 330 papers that were submitted. Steven Falowski, MD, will deliver the podium talk to discuss: Functional Outcomes in the Low Back Pain Subject with a Novel Interspinous Fusion Device: REFINE Study 12 Month Results.

Later that day, Aurora Spine will be sponsoring the ASPN Charity Reception with beneficiaries being the IRONMAN Foundation and Return to Duty.

“We are very excited about this year’s ASPN Conference, especially having been selected for a podium talk that highlights our ZIP series of products. We are extremely honored to be selected for this discussion, as there are only a few spots for selection,” said Trent Northcutt, President and CEO of Aurora Spine. “We are also excited about this year’s ASPN Conference as we’ll be introducing our AERO Lumbar Fusion System to industry professionals in attendance, which will include in excess of 3,000 industry professionals including neuro, ortho and pain interventionalists.”

For more information about the conference go to: ASPN Annual Conference July 2025.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of proprietary, minimally invasive, and regenerative technologies. The company is committed to improving surgical outcomes through innovation, efficiency, and patient-centered design.

For more information, visit: www.aurora-spine.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, many of which are beyond Aurora Spine’s control. Forward-looking statements include, but are not limited to, statements regarding the expected use and success of the Company’s products, including the AERO Lumbar Fusion System. Actual results may differ materially. Please refer to Aurora Spine’s final prospectus and public filings for additional information on risks and uncertainties.
These forward-looking statements speak only as of the date of this release. Aurora Spine undertakes no obligation to revise or update them to reflect future events or circumstances.

Contacts:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Investor Contact:
Adam Lowensteiner
Lytham Partners
(646) 829-9702
Email: asapf@lythampartners.com

Not for distribution to U.S. newswire services or dissemination in the United States.